Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Revolution Medicines

Some Pancreatic Cancer Families Hit Insurance Delays After Rasonque Approval Closed the Drug's Free Early Access Program

FDA approval of the pancreatic cancer pill Rasonque closed its free early access program before some insurers were ready to cover it.

Medical Daily

Revolution Medicines Got Its Breakthrough—What Moves It Next?

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

MarketBeat

A Pancreatic Cancer Drug Shrank Lung Tumors in an Early Trial, but Four Patients Died from Adverse Events

Daraxonrasib shrank tumors in RAS-mutant lung cancer in an early trial, but most patients had side effects, and four died.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

New Cancer Med Is Giving Patients Hope, But One Former Senator Says It Comes With A “Nasty” Catch

The FDA has approved a new cancer treatment. It's a tablet meant to help patients with pancreatic cancer. But the side-effects can be brutal, and visually shocking, despite its success rate. The full story is in the article.

Bored Panda

Pancreatic Cancer Patients No Longer Need Expanded Access to Get a RAS Inhibitor After Federal Approval

FDA approved daraxonrasib for metastatic pancreatic adenocarcinoma, replacing a case by case expanded access route with a prescribable therapy.

Medical Daily

A Once-Daily Pill for Pancreatic Cancer Just Won Approval, and It Nearly Doubled Survival in Trial

FDA approved Rasonque for metastatic pancreatic adenocarcinoma. A phase 3 trial found median survival of 13.2 months against 6.7 on chemotherapy.

Medical Daily

A pill that doubles survival: Revolution's FDA-approved drug gives pancreatic cancer patients a fighting chance

The US FDA has approved Revolution Medicines' pancreatic cancer drug Rasonque. This once-daily pill doubles survival for patients with advanced metastatic pancreatic cancer. Rasonque blocks the RAS protein, which drives tumor growth in many pancreatic cancers. Doctors hail this development as a significant breakthrough in cancer treatment. The drug is…

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

FDA approves new drug Rasonque to treat advanced pancreatic cancer

The US FDA on Wednesday approved Revolution Medicines' Rasonque for advanced pancreatic cancer, opening a new treatment option for patients with metastatic disease. A large trial found the once-daily pill doubled survival rates, offering fresh hope for people who have exhausted other treatments.

France 24

Why Wall Street sees a $39,800 pancreatic cancer pill as proof of a much bigger bet

Dr. Danish Nagda, a shareholder in the developer, told Fortune it was "incredibly exciting ... maybe half a decade away from the post-cancer era."

Fortune

New hope for pancreatic cancer patients after FDA approves drug shown to improve survival

Pancreatic cancer is among the deadliest forms, largely because detection is difficult before malignancy spreads to other organs

The Independent UK

FDA approves landmark pancreatic cancer drug that's shown to improve survival

U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer

The Independent UK

FDA Accepts Review of a Pancreatic Cancer Pill Already Reaching Patients Through an Expanded Access Program

The FDA accepted the daraxonrasib application in July, and more than 2,000 patients are already receiving the drug without approval.

Medical Daily

A New Pancreatic Cancer Drug Is Reaching Patients Before Approval and the Testing Rules Are Not What Many Assume

Daraxonrasib is reaching pancreatic cancer patients through expanded access, and the pivotal trial enrolled them regardless of RAS mutation status.

Medical Daily

National Cancer Survivors Day Is Sunday — And for Dallas's Pancreatic Cancer Patients, There Has Never Been More Reason to Celebrate

National Cancer Survivors Day arrives with unprecedented hope for Dallas-Fort Worth pancreatic cancer patients as a breakthrough new drug nearly doubles survival in a landmark Phase 3 trial, marking a major advance against one of the deadliest cancers.

Medical Daily

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

"Transformative Advance" in Cancer Treatment Emerges in Dallas — New Pill Shows Rare Survival Jump in Pancreatic Cancer Patients

Pancreatic Cancer treatment may be entering a new era as a breakthrough pill nearly doubles survival in metastatic patients, offering new hope for one of the deadliest forms of cancer.

The Conversation

Breakthrough drug nearly doubles survival with advanced pancreatic cancer – an oncologist explains how daraxonrasib overcame an ‘undruggable’ disease

For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of their diagnosis.

Barchart

Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy?

Revolution Medicines stock rallies on impressive daraxonrasib Phase 3 results. Here’s why RVMD shares may sustain the momentum moving forward.

The Independent UK

New cancer drug shows potential to double patients’ survival time

IN FULL

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

New pancreatic cancer drug nearly doubles survival time in patients

Pancreatic cancer is the only cancer with a five-year survival rate that’s below 20%

Barchart

This Oncology Stock Just Hit New All-Time Highs

Revolution Medicines (RVMD) is trading at fresh all-time highs. RVMD exhibits strong technical momentum with a 100% technical “Buy” opinion from Barchart. Shares are up nearly 60% over the past year. Wall Street analysts are overwhelmingly bullish on RVMD, although sentiment is mixed across other platforms. Today’s Featured Stock Valued...

Benzinga

Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Friday.

Benzinga

Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug

Revolution Medicines, Inc. (NASDAQ:RVMD) stock is trading higher after the company shared updates from its Daraxonrasib Phase 1 trials on Wednesday.

Benzinga

Revolution Medicines's Return On Capital Employed Overview

Revolution Medicines (NASDAQ:RVMD) brought in sales totaling $7.58 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 9.44%, resulting in a loss of $57.65 million.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022

Upgrades

Benzinga

Revolution Medicines's Earnings Outlook

Revolution Medicines (NASDAQ:RVMD) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Revolution Medicines will report an earnings per share (EPS) of $-0.77.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the American Cancer Society

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.